Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
12.91
+0.26 (2.06%)
At close: Jan 29, 2026, 4:00 PM EST
12.90
-0.01 (-0.08%)
After-hours: Jan 29, 2026, 4:00 PM EST
Enanta Pharmaceuticals Employees
Enanta Pharmaceuticals had 120 employees as of September 30, 2025. The number of employees decreased by 11 or -8.40% compared to the previous year.
Employees
120
Change (1Y)
-11
Growth (1Y)
-8.40%
Revenue / Employee
$544,367
Profits / Employee
-$682,408
Market Cap
372.62M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2025 | 120 | -11 | -8.40% |
| Sep 30, 2024 | 131 | -14 | -9.66% |
| Sep 30, 2023 | 145 | -15 | -9.38% |
| Sep 30, 2022 | 160 | 5 | 3.23% |
| Sep 30, 2021 | 155 | 14 | 9.93% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Autolus Therapeutics | 650 |
| Rocket Pharmaceuticals | 299 |
| Entrada Therapeutics | 183 |
| AC Immune | 172 |
| Aura Biosciences | 109 |
| Neumora Therapeutics | 95 |
| Lineage Cell Therapeutics | 77 |
| PepGen | 57 |
ENTA News
- 14 days ago - Enanta Pharmaceuticals, Inc. (ENTA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 21 days ago - Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook - Business Wire
- 24 days ago - Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development - Seeking Alpha
- 2 months ago - Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025 - Business Wire
- 3 months ago - Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
- 3 months ago - Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025 - Business Wire
- 4 months ago - Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025 - Business Wire